Patents by Inventor Miklos Peterfy

Miklos Peterfy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene associated with regulation of adiposity and insulin response
    Patent number: 6869766
    Abstract: This invention pertains to the identification and isolation of a gene implicated in the fatty liver dystrophy (fld) phenotype. Mouse and human forms of the novel gene, designated herein as Lpin1/LPIN1 (mouse and human genes, respectively), are identified. This invention additionally provides methods of screening for agents that alter adipose tissue development. The methods involve contacting a cell containing a Lpin1 gene with a test agent; and detecting a change in the expression or activity of a Lpin1 gene product, where a difference in the expression or activity of Lpin1 in the contacted cell indicates that the agent alters or is likely to alter adipose tissue development. Also provided are methods of identifying Lpin1 mutations, and methods of mitigating symptoms of lipodystrophy, obesity, diabetes, atherosclerosis and related pathologies.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: March 22, 2005
    Assignee: The Regents of the University of California
    Inventors: Karen Reue, Miklós Péterfy
  • Novel gene associated with regulation of adiposity and insulin response
    Publication number: 20020152483
    Abstract: This invention pertains to the identification and isolation of a gene implicated in the fatty liver dystrophy (fld) phenotype. Mouse and human forms of the novel gene, designated herein as Lpin1/LPIN1 (mouse and human genes, respectively), are identified. This invention additionally provides methods of screening for agents that alter adipose tissue development. The methods involve contacting a cell containing a Lpin1 gene with a test agent; and detecting a change in the expression or activity of a Lpin1 gene product, where a difference in the expression or activity of Lpin1 in the contacted cell indicates that the agent alters or is likely to alter adipose tissue development. Also provided are methods of identifying Lpin1 mutations, and methods of mitigating symptoms of lipodystrophy, obesity, diabetes, atherosclerosis and related pathologies.
    Type: Application
    Filed: December 19, 2001
    Publication date: October 17, 2002
    Applicant: The Regents of the University of California
    Inventors: Karen Reue, Miklos Peterfy